Role of hepatoma‐derived growth factor in promoting de novo lipogenesis and tumorigenesis in hepatocellular carcinoma

Xuejie Min, Jun Wen, Li Zhao, Kaiying Wang, Qingli Li, Gang Huang, Jianjun Liu, Xiaoping ZhaoMolecular 2018 · DOI

TL;DR

This study reveals that hepatoma-derived growth factor (HDGF) promotes hepatocellular carcinoma (HCC) by activating lipid synthesis through its nuclear localization and interaction with the SREBP-1 transcription factor. Specifically, the PWWP domain of HDGF is crucial for this process, and its dysregulation is linked to poor patient prognosis, suggesting a potential therapeutic target.

What Problem Does This Paper Address?

Hepatocellular carcinoma (HCC) is a major global health concern, and understanding the molecular mechanisms driving its development and progression is critical for effective treatment. While HCC cells exhibit altered lipid metabolism, particularly increased de novo lipogenesis (the synthesis of fatty acids), the precise role of specific factors in this process remains unclear. Hepatoma-derived growth factor (HDGF), a known growth factor, has been implicated in various cancers, but its specific contribution to HCC tumorigenesis, especially concerning lipid metabolism, was not well understood. This paper aims to elucidate the mechanism by which HDGF promotes HCC, focusing on its role in regulating lipid metabolism and its association with patient outcomes.

Methods

The researchers employed a multi-faceted approach:

  • Immunohistochemistry: To assess HDGF expression (both nuclear and cytoplasmic) in HCC tissues and correlate it with patient prognosis and clinicopathological features.
  • RNA-sequencing (RNA-Seq) and Gene Set Enrichment Analysis (GSEA): To identify biological pathways and gene sets affected by HDGF knockdown, particularly those related to lipid metabolism.
  • Quantitative Real-Time PCR (qPCR): To validate RNA-Seq findings and measure the expression levels of specific lipogenic genes.
  • Western Blotting: To detect protein levels of HDGF, SREBP-1, and other relevant proteins.
  • Coimmunoprecipitation (Co-IP) and GST Pull-down Assays: To investigate direct protein-protein interactions between HDGF and SREBP-1, and HDGF with CTBP1.
  • Luciferase Reporter Assays: To assess the transcriptional activity of the FASN promoter, a key lipogenic gene.
  • Cell Viability and Colony Formation Assays: To evaluate the impact of HDGF on HCC cell proliferation and tumorigenicity.
  • Oil Red O Staining: To visualize and quantify intracellular lipid droplets.
  • Triglyceride and Cholesterol Assays: To measure the levels of these key lipids in cells.
  • Immunofluorescence Staining: To visualize the subcellular localization of HDGF and SREBP-1.
  • Site-directed Mutagenesis: To alter the PWWP domain of HDGF (specifically, changing a proline to alanine, creating an "A-type" mutant) to study its functional significance.
  • Xenograft Studies: To assess the in vivo effect of HDGF and its mutants on tumor growth.

Datasets

The study utilized:

  • Human HCC Tissue Samples: For immunohistochemistry and correlation with clinical data.
  • HepG2, HEK293T, and SMMC-7721 Cell Lines: These are standard human cancer cell lines used for in vitro experiments.
  • ENCODE Project Data: Specifically, RNA-Seq data from HepG2 cells with HDGF knockdown was used for initial GSEA analysis.
  • Publicly Available Gene Set Databases: Such as MSIGDB_V6.1, for GSEA analysis.

Key Insights and Ideas

  • Nuclear HDGF is Key: The study strongly suggests that it's the nuclear localization of HDGF, not cytoplasmic, that is significantly associated with poor prognosis in HCC. This highlights the importance of subcellular localization for protein function.
  • HDGF as a Lipogenesis Maestro: HDGF acts as a crucial coactivator for SREBP-1, a master regulator of lipid synthesis. It essentially "turns up the volume" on genes responsible for creating fatty acids and cholesterol.
  • The PWWP Domain is the Conductor: The PWWP domain of HDGF is not just a structural element; its specific type (P-type vs. A-type) dictates HDGF's ability to promote lipogenesis. The P-type is essential for its function.
  • CTBP1 as a Molecular Brake: The P-type PWWP domain of HDGF seems to work by blocking the recruitment of CTBP1, a transcriptional repressor, to the promoters of lipogenic genes. This "releases the brakes" on lipid synthesis.
  • Synergistic Prognostic Marker: The combined high expression of nuclear HDGF and SREBP-1 is a powerful predictor of poor survival in HCC patients, suggesting a critical axis in disease progression.

Key Results

  • HDGF Overexpression and Prognosis: High nuclear HDGF expression was significantly correlated with poor differentiation, advanced clinical stage, and reduced overall survival in HCC patients.
  • HDGF Knockdown Impairs Lipogenesis: Knocking down HDGF in HCC cells led to significantly reduced expression of genes involved in fatty acid, steroid, and cholesterol biosynthesis.
  • SREBP-1 Activation: HDGF promotes the transcription of lipogenic genes primarily through the activation of the SREBP-1 transcription factor.
  • PWWP Domain Cruciality: Mutating the PWWP domain of HDGF from P-type to A-type (P24A mutant) significantly impaired its ability to induce SREBP-1-mediated gene transcription and promote lipogenesis. The A-type mutant also showed reduced nuclear abundance.
  • HDGF and CTBP1 Interaction: The P-type PWWP domain of HDGF appears to inhibit SREBP-1-mediated transcription by preventing the recruitment of the transcriptional repressor CTBP1 to the promoter of target genes.
  • Lipid Levels and Cell Growth: HDGF promotes triglyceride and cholesterol biosynthesis, and its presence (especially the A-type mutant) enhances HCC cell proliferation and tumor growth in vivo.
  • Coexpression Predicts Poor Survival: A strong positive correlation was found between nuclear HDGF and SREBP-1 expression in HCC tissues, with coexpression predicting significantly poorer patient survival.

Limitations and Future Work

  • Receptor-Mediated vs. Direct Action: While HDGF is identified as a growth factor, its specific receptor on the cell membrane remains unclear. The study suggests HDGF acts more directly as a nuclear cofactor, but further investigation into potential receptor interactions could be beneficial.
  • Mechanism of Nuclear Translocation: While nuclear localization is shown to be critical, the precise mechanisms governing HDGF's translocation into the nucleus and its regulation could be further explored.
  • Broader Impact of HDGF: The study focuses on lipid metabolism, but HDGF is known to regulate other cellular processes. Future work could investigate how HDGF's role in lipogenesis intersects with its other functions (e.g., cell division, angiogenesis) in HCC progression.
  • Therapeutic Strategies: The findings highlight the HDGF/SREBP-1 axis as a potential therapeutic target. Developing specific inhibitors or modulators of this pathway could be a promising avenue for future research and drug development for HCC.

Summary updated

Abstract

Although identified as a growth factor, the mechanism by which hepatoma-derived growth factor (HDGF) promotes cancer development remains unclear. We found that nuclear but not cytoplasmic HDGF is closely associated with prognosis of hepatocellular carcinoma (HCC). RNA-sequencing analysis further demonstrated that the nuclear role of HDGF involved regulation of transcription of lipid metabolism genes. HDGF-induced expression of lipogenic genes was mainly associated with activation of sterol regulatory element binding protein (SREBP) transcription factor. Coexpression of SREBP-1 and nuclear HDGF predicts poor prognosis for HCC. In addition, by changing the first amino acid of the PWWP domain from proline to alanine, the type of PWWP domain changed from P- to A-type, resulting in inability to induce SREBP-1-mediated gene transcription. The type of PWWP domain affects the recruitment of the C-terminal binding protein-1 transcriptional repressor on the promoter of the lipogenic gene. Our data indicate that HDGF acts as a coactivator of SREBP1-mediated transcription of lipogenic genes. The PWWP domain is crucial for HDGF to promote lipogenesis. Moreover, transcriptional regulation of nuclear HDGF plays important roles in the development of HCC.
BibTeX
@inproceedings{min2018role,
  author = {Xuejie Min and Jun Wen and Li Zhao and Kaiying Wang and Qingli Li and Gang Huang and Jianjun Liu and Xiaoping Zhao},
  title = {{Role of hepatoma‐derived growth factor in promoting <i>de novo</i> lipogenesis and tumorigenesis in hepatocellular carcinoma}},
  booktitle = {Molecular},
  year = {2018},
  doi = {10.1002/1878-0261.12357},
}
Figure